Remdesivir for the Treatment of Covid-19 — Preliminary Report

Remdesivir for the Treatment of Covid-19 — Preliminary Report
627.33 kB
01. Jun 2020
8 x

2. Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. New England Journal of Medicine. 2020;.

Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious.

We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infectioncontrol purposes only.

A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan- Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%).

Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 number, NCT04280705.)

Powered by Phoca Download


Sobre la SOMETH

La Sociedad Mexicana de Trombosis y Hemostasia (SOMETH) es una asociación civil sin fines lucrativos, integrada por profesionales de la salud que se dedican al estudio, prevención, diagnóstico y tratamiento de las enfermedades asociadas a cualquier tipo de trombosis y/o trastornos de la hemostasia.

Síganos en nuestras redes:

insta face twitter social youtube circle 512

Nos han Visitado

Hoy 4

Esta Semana 72

Este mes 498

Todos 77669

lets encrypt

Enlaces Sociedades Mexicanas

Enlaces Sociedades Extranjeras

©2022 Sociedad Mexicana de Trombosis y Hemostasia. Derechos Reservados. Desarrollo